Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12375166 | 0.89 | HSD11B1 (0.37) | ALOX5HSD11B1DPP4KCNH2DPP8 | |
| SCHEMBL25895229 | 0.89 | ROCK2 (0.33) | ROCK2ROCK1ALOX5LMNATDP1 | |
| SCHEMBL10232745 | 0.83 | ROCK2 (0.40) | ROCK2ROCK1ALOX5LMNATDP1 | |
| SCHEMBL25895252 | 0.82 | — | — | |
| SCHEMBL15199107 | 0.82 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL16727377 | 0.82 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL7603415 | 0.81 | RIPK1 (0.35) | HSD11B1 | |
| SCHEMBL12375165 | 0.81 | CES2 (0.39) | HSD11B1 | |
| SCHEMBL1911777 | 0.79 | CES2 (0.42) | — | |
| SCHEMBL15431472 | 0.77 | EPHX2 (0.34) | LMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |